Dirozalkib
Dirozalkib (Compound 4) is the inhibitor for ALK with an IC50 of 0.9 nM. Dirozalkib exhibits anti-proliferative activity in cancer cells NCI-H3122, Karpas-299 and NCI-H2228 with IC50s of 130.4, 0.71 and 15.11 nM, respectively. Dirozalkib exhibits good pharmacokinetics characteristics with an bioavailbility of 30%~50%[1].
Product Specifications
CAS Number
1893419-37-8
UNSPSC
12352005
Target
Anaplastic lymphoma kinase (ALK)
Related Pathways
Protein Tyrosine Kinase/RTK
Field of Research
Cancer
Smiles
O=S(C1=C(NC2=NC(NC3=C4OCCOC4=C(C5CCNCC5)C(C)=C3)=NC=C2Cl)C=CC=C1)(C(C)C)=O
Molecular Formula
C27H32ClN5O4S
Molecular Weight
558.09
References & Citations
[1]Wu Y, et al., Polycyclic anaplastic lymphoma kinase inhibitor. WO2016050171
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
M2749-02-01 25 µg
Mcl 1 (Myeloid Cell Leukemia 1, Mcl-1, Bcl 2 Related Protein EAT/Mcl1, Bcl2 Related, EAT, Induced Myeloid Leukemia Cell Differentiation Protein, Mcl1/EAT, MCL1L, MCL1S, MGC104264, MGC1839, Myeloid Cell Leukemia Sequence 1, TM) discontinued
Sign In for Pricing
View Details M2749-02-02 100 µg
Mcl 1 (Myeloid Cell Leukemia 1, Mcl-1, Bcl 2 Related Protein EAT/Mcl1, Bcl2 Related, EAT, Induced Myeloid Leukemia Cell Differentiation Protein, Mcl1/EAT, MCL1L, MCL1S, MGC104264, MGC1839, Myeloid Cell Leukemia Sequence 1, TM) discontinued
Sign In for Pricing
View Details